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Seroprevalence surveys in sub-Saharan Africa: what do they 
tell us?
Initial estimates of the potential effect of SARS-
CoV-2 virus in sub-Saharan Africa were catastrophic:1 
fortunately, these predictions have not been met in 
terms of number of cases, deaths, and saturation of 
health systems. On one hand, since ageing is the main 
risk factor for COVID-19,2 the young population in 
sub-Saharan Africa partly explains the low number of 
cases and deaths registered. On the other hand, the 
limited testing capacity in many sub-Saharan Africa 
countries, accompanied by stigmatisation, might result 
in underestimation of the magnitude of transmission. 
Underestimation of the true burden of COVID-19 has 
been indicated by seroprevalence studies in several 
sub-Saharan Africa countries.3–5 However, most of these 
studies were done in specific groups that might not be 
representative of the general population. In The Lancet 
Global Health, Lloyd Mulenga and colleagues6 describe 
the first large population-based seroprevalence survey 
in the region (covering six districts in Zambia) to 
determine the extent of SARS-CoV-2 transmission in 
the country. To complement overall rates of infection, 
the investigators also collected nasopharyngeal swabs 
to determine SARS-CoV-2 prevalence by real-time PCR 
(rtPCR) and thus ongoing infection in the population 
since the survey was done during the first wave of the 
epidemic.
Two main findings from the study by Mulenga and 
colleagues contribute to the growing evidence of 
under-reporting and the mild symptomatology of 
SARS-CoV-2 infection in sub-Saharan Africa. First, the 
study indicates that official data on the number of 
laboratory-confirmed cases are largely underestimating 
the extent of community transmission. According to 
the study, only one laboratory-confirmed case was 
reported for every 92 SARS-CoV-2 infections that 
occurred in the community.6 Only 2·3% of individuals 
with a positive rtPCR test were aware of their infection 
and only 8·2% of individuals with SARS-CoV-2 
antibodies were aware that they had been infected 
because they had not been tested. At the time of the 
survey (July 4–27, 2020), fewer than 5000 cases had 
been reported in Zambia, whereas the study data 
indicated that an estimated 454 708 SARS-CoV-2 
infections (95% CI 312 705–596 713) had occurred 
in the six participating districts between March and 
July, 2020. Absence of systematic surveillance and 
testing strategies are possible factors that might have 
contributed to these differences, which have also been 
observed in other settings.7 Widespread misinformation 
in the community and the stigma associated with 
COVID-19 are also important factors, which result in 
avoidance of testing and self-medication.8
Second, most of the cases identified by the study were 
asymptomatic or had mild symptoms. Discrepancies 
between official numbers and infections measured by 
the survey can also be explained by this high prevalence 
of asymptomatic infections, since most testing strategies 
focus on patients who are symptomatic. This finding 
is consistent with other studies done in Africa,5 and is 
aligned with the community belief of unjustified national 
and international response to the virus. With time, 
Zambians became less adherent to prevention measures 
due to the perception of low personal risk.6
Mulenga and colleagues should be commended for 
the timeliness of their survey and swift reporting of 
results. Seroprevalence surveys done during the peak 
of the pandemic are likely to underestimate the true 
magnitude of COVID-19 in the community; therefore, 
inclusion of PCR testing in this study was beneficial 
to identify both recent (ie, in the past 2–3 weeks) and 
past infections. If most of infections in the continent 
are indeed asymptomatic, seroprevalence studies 
might underestimate the true extent of transmission, 
since antibody response is proportional to severity 
of infection.9 However, only half of the participants 
agreed to provide samples for both PCR and ELISA 
and, therefore, overall infection rate is probably higher 
than reported in the survey. One limitation of the 
study design is that it is difficult to estimate the overall 
transmission at the end of the first wave of COVID-19 
infections.
Although the majority of cases of COVID-19 have 
been mild in sub-Saharan Africa, the overall impact 
of the pandemic is yet to be quantified. Studies 
on excess mortality in African countries such as 
Zambia are necessary to measure the overall direct 
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and indirect impact on mortality. Additionally, the 
prompt response of the Zambian Government, which 
included the closure of borders, curfews, and school 
closures, could have additional indirect effects, which 
should be weighed against the direct effects of the 
pandemic. The overall impact of the pandemic needs 
to be monitored while accurate information is shared 
with the public to encourage communities to comply 
with the restrictions. As noted by the authors, most 
Zambians remained susceptible to SARS-CoV-2 
infection at the time of their survey, thus the higher 
number of COVID-19 cases reported in the second 
wave in that country that began towards the end 
of December, 2020, is not surprising. A follow-up 
seroprevalence survey will be useful as the epidemic 
continues and plans for vaccination advance.
In sub-Saharan African settings with laboratory 
capacity, we advocate for seroprevalence studies 
whenever possible. Furthermore, combining these 
studies with excess mortality studies would provide 
reliable data to support governments to make decisions 
on how to manage the pandemic and reduce the health 
and socioeconomic impact. Ultimately, to understand 
transmission in Zambia and the sub-Saharan African 
region, asymptomatic surveillance is warranted.
We declare no competing interests.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open 
Access article under the CC BY-NC-ND 4.0 license.
*Effua Usuf, Anna Roca
eusuf@mrc.gm
Department of Disease Control and Elimination, Medical Research Council Unit 
The Gambia at London School of Hygiene and Tropical Medicine, Fajara, 
The Gambia
1 Massinga Loembe M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO, 
Nkengasong JN. COVID-19 in Africa: the spread and response. Nat Med 
2020; 26: 999–1003.
2 de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 
among patients in the Oxford Royal College of General Practitioners 
Research and Surveillance Centre primary care network: a cross-sectional 
study. Lancet Infect Dis 2020; 20: 1034–42.
3 Chibwana MG, Jere KC, Kamng’ona R, et al. High SARS-CoV-2 
seroprevalence in health care workers but relatively low numbers of deaths 
in urban Malawi. medRxiv 2020; published online Aug 5. https://doi.
org/10.1101/2020.07.30.20164970 (preprint).
4 Uyoga S, Adetifa IMO, Karanja HK, et al. Seroprevalence of anti-SARS-
CoV-2 IgG antibodies in Kenyan blood donors. Science 2021; 371: 79–82.
5 Olayanju O, Bamidele O, Edem F, et al. SARS-CoV-2 seropositivity in 
asymptomatic frontline health workers in Ibadan, Nigeria. 
Am J Trop Med Hyg 2021; 104: 91–94.
6 Mulenga LB, Hines JZ, Fwoloshi S, et al. Prevalence of SARS-CoV-2 in 
six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. 
Lancet Glob Health 2021; published online March 9. https://doi.
org/10.1016/S2214-109X(21)00053-X.
7 Mendelson M, Madhi S. South Africa’s coronavirus testing strategy is broken 
and not fit for purpose: it’s time for a change. S Afr Med J 2020; 110: 429–31.
8 Sadio AJ, Gbeasor-Komlanvi FA, Konu RY, et al. Assessment of self-
medication practices in the context of the COVID-19 outbreak in Togo. 
BMC Public Health 2021; 21: 58.
9 Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of 
asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26: 1200–04.
For more on the number of 
COVID-19 cases in Zambia see 
https://www.worldometers.info/
coronavirus/country/zambia/
